FastWave Medical Garners ‘Fierce 15’ Honor Amid Eighth U.S. Patent Win for IVL Innovation

The recognition underscores FastWave’s rising prominence in intravascular lithotripsy, as the company expands its intellectual property portfolio and momentum in cardiovascular innovation.

FastWave Medical’s inclusion in the Fierce Medtech 2024 “Fierce 15” list marks a significant recognition of the company’s bold innovation in intravascular lithotripsy (IVL). This prestigious accolade highlights FastWave as one of the most promising private medtech companies, celebrating its disruptive approach and execution strength in the competitive vascular intervention space. The recognition coincides with the company’s latest achievement—securing its eighth U.S. patent for the Artero™ electric IVL (E-IVL) platform, a next-generation solution designed to address long-standing limitations in peripheral artery disease treatment.

FastWave’s Artero™ system stands out by offering circumferential sonic pressure waves at a frequency of 4 Hz—doubling the speed of traditional IVL devices—while maintaining precision, safety, and physician ease-of-use. With its hands-free design, simplified interface, real-time feedback, and lower crossing profile, Artero™ enables efficient modification of arterial calcium even in challenging anatomies. This technology empowers interventional radiologists and vascular specialists with greater procedural control and consistency, ultimately enhancing clinical outcomes and reducing treatment times for patients suffering from peripheral artery disease.

Sign up for Blog Updates